Sentences with phrase «renal cell carcinomas»
Renin - producing renal cell carcinomas — clinical and experimental investigations on a special form of renal hypertension
https://www.semanticscholar.org/
Studies of Gluts in human tumors have shown a significant increase in the abundance of Glut1 and Glut3 mRNA in cancers of the esophagus, colon, and pancreas, overexpression of Glut1 and Glut3 mRNA and Glut1 protein expression in head and neck tumors and Glut1 protein overexpression in breast and renal cell carcinomas
Most renal cell carcinomas are a subtype called clear cell carcinoma.
A population - based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas.
About 9 out of every 10 kidney cancers are renal cell carcinomas — cancers that form in the lining of the tubules inside the kidney.
«Most renal cell carcinomas learn to escape therapy after a couple of years,» said Robert Weiss, professor of medicine at UC Davis, chief of nephrology at Sacramento VA Medical Center, and head of the kidney cancer working group at the UC Davis Comprehensive Cancer Center.
The researchers began by identifying the genes that often mutate in human renal cell carcinomas.
In the last few years, much progress has been made in this field of cancer research, also for the treatment of renal cell carcinomas.
Researchers studied food questionnaires for 335 people with renal cell carcinoma, the most common form of kidney cancer, and 337 healthy controls.
Mr. Kaisary's main interest is the diagnosis and management of prostate cancer and benign prostate disease together with bladder cancer and renal cell carcinoma.
Renal cell carcinoma, also known by the eponym Grawitz tumor, is the most common form of kidney cancer arising from the renal tubule.
Spontaneous remission is more likely with certain kinds of cancer, such as melanoma and renal cell carcinoma.
The most common form of this disease is called clear cell renal cell carcinoma (ccRCC).
Despite decades of effort, however, researchers were unable to develop a mouse model of renal cell carcinoma — until now.
A phase I clinical trial conducted by investigators at the University of Texas San Antonio, showed that the combination of HCQ and the chemotherapy drug vorinostat in 27 patients with advanced solid tumors, including renal cell carcinoma and colon cancer, was clinically safe and inhibited autophagy.
An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases when given to animals.
The Ogretmen laboratory screened previously reported microarray data sets of several human tumor tissues (metastatic head and neck squamous cell carcinoma, melanoma, and renal cell carcinoma) and showed that, in these samples, only the levels of CerS4 were significantly decreased.
Javidnia says analysis in this study shows pazopanib penetrates the mice's blood - brain barrier when given the equivalent of half of dose given for renal cell carcinoma treatment.
However, death rates due to renal cell carcinoma (kidney cancer) have not decreased, indicating that surgery may be of little or no benefit to some patients.
In previous studies, including recent genome sequencing of cancer patients, human SETD2 has been implicated in several cancer types, especially in renal cell carcinoma — the most common kind of kidney cancer.
Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib.
Chi said the study points to a promising new approach for the treatment of renal cell carcinoma, a form of kidney cancer that has historically been very difficult to cure.
About three - fourths of renal cell carcinoma cases are marked by a missing VHL tumor - suppressor gene, which keeps healthy cells from developing into tumors.
The article, titled «Entinostat Neutralizes Myeloid Derived Suppressor Cells and Enhances the Antitumor Effect of PD - 1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma,» was published in Clinical Cancer Research and is available online.
Cimetidine has been shown to have positive effects in colorectal and gastric cancer, melanoma, and renal cell carcinoma.
The results from our new study suggest that entinostat may enhance the anti-tumor efficacy of PD - 1 targeted therapy through MDSC targeting, potentially providing an effective combination treatment approach for patients with solid tumors, including lung and renal cell carcinoma.»
«Preclinical results support entinostat's role in targeting the tumor microenvironment: Entinostat inhibits function of myeloid derived suppressor cells resulting in enhanced antitumor effect in murine models of lung and renal cell carcinoma.»
Wherry, together with his colleagues in the Parker Institute for Cancer Immunotherapy at Penn, are involved in multiple checkpoint - related trials, in melanoma, lung cancer, renal cell carcinoma, and others, including combining checkpoint blockade with radiation.
Renal cell carcinoma, the most common form of kidney cancer, is expected to be diagnosed in over 60,000 new patients this year and claim approximately 14,000 lives, according to the American Cancer Society.
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.
Charles Swanton, a cancer geneticist at the Francis Crick Institute in London, and colleagues analyzed 1,206 clear - cell renal cell carcinoma (ccRCC) tumor samples from 101 patients as part of the Tracking Cancer Evolution through therapy (TRACERx) program.
Based on these preclinical findings, CRI provides a seed grant for a phase I clinical trial to test the strategy in patients with metastatic renal cell carcinoma.
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form...
PHIII Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.
A Phase III, Multicenter, Randomized, Placebo - Controlled, Double - Blind Study Of Atezolizumab (Anti − PD - L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy
MiR - 514a - 3p inhibits cell proliferation and epithelial - mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma.
Axitinib, a drug used to treat renal cell carcinoma, has been shown to be effective at inhibiting the Abl kinase activity in patients with BCR - ABL1 (T315I).
The company's lead product is for the personalized treatment of advanced renal cell carcinoma and is in phase III clinical development.
Gene transfer of the Co-stimulatory molecules B7 - 1 and B7 - 2 enhances the immunogenicity of human renal cell carcinoma to a different extent.
High - dose interleukin - 2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.
Costimulatory B7 - H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Vascularity of primary and metastatic renal cell carcinoma specimens.
Background: Expression of programmed death ligand (PD - L1 / B7 - H1 / CD274) represents a mechanism of immune escape for renal cell carcinoma (RCC) cells.
The treatment of renal cell carcinoma with human leukocyte alpha - interferon.
Tumor B7 - H1 is associated with poor prognosis in renal cell carcinoma patients with long - term follow - up.
Costimulatory molecule B7 - H1 in primary and metastatic clear cell renal cell carcinoma.
In an effort to further exploit the potential of Pexa - Vec to activate the immune system to fight cancer, as seen in McDonald's preclinical data, SillaJen recently announced a new clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's team.
Robert Motzer, M.D., of Memorial Sloan Kettering Cancer Center, presented results from a phase 2 trial of nivolumab in renal cell carcinoma (RCC), commonly known as kidney cancer.
According to the researchers, «the combination of an antibody that inhibits PD - L1 and PD - 1 [programmed death 1] interactions with a targeted antiangiogenic agent might take advantage of complementary mechanisms of action to provide clinical benefit in patients with advanced renal cell carcinoma that exceeds the effects of the respective drugs alone, without increasing associated toxicity.»